Advertisement

Meta-analysis Comparing the Effects of Rosuvastatin Versus Atorvastatin on Regression of Coronary Atherosclerotic Plaques

      Rosuvastatin and atorvastatin both are high-intensity statins. However, which statin is more effective for the reversion of coronary atherosclerotic plaques remains inconclusive. We, therefore, conducted a meta-analysis to provide further evidence for proper statin selection. Pubmed, The Cochrane Library, Embase, Chinese BioMedicine, and China National Knowledge Infrastructure databases were systematically searched for eligible publications. We also manually reviewed the references from all relevant literature for more trials. Only studies that met our predefined inclusion criteria up to March 31, 2015, were enrolled. Five randomized controlled trials, 4 published in English and 1 in Chinese, were finally included in our study with a total of 1,556 participants, of whom 772 were in the rosuvastatin group and 784 in the atorvastatin group. The dose ratios of rosuvastatin versus atorvastatin were 1:2 in all included trials. Pooling across the studies demonstrated that compared with atorvastatin, rosuvastatin administration further reduced the total atheroma volume (weighted mean difference [WMD] −1.61 mm3, 95% confidence interval [CI] −2.70 to −0.52; p = 0.004) and percent atheroma volume (WMD −0.34%, 95% CI −0.64 to −0.03; p = 0.03) and improved the lumen volume more significantly (WMD 2.10 mm3, 95% CI 0.04 to 4.17; p = 0.046). The comparative regression of plaques was not different across subgroups. In conclusion, rosuvastatin is superior to atorvastatin in the reversion of coronary atherosclerotic plaques.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Libby P.
        • Theroux P.
        Pathophysiology of coronary artery disease.
        Circulation. 2005; 111: 3481-3488
        • Dohi T.
        • Miyauchi K.
        • Okazaki S.
        • Yokoyama T.
        • Yanagisawa N.
        • Tamura H.
        • Kojima T.
        • Yokoyama K.
        • Kurata T.
        • Daida H.
        Plaque regression determined by intravascular ultrasound predicts long-term outcomes of patients with acute coronary syndrome.
        J Atheroscler Thromb. 2011; 18: 231-239
        • Puri R.
        • Nissen S.E.
        • Shao M.
        • Ballantyne C.M.
        • Barter P.J.
        • Chapman M.J.
        • Erbel R.
        • Libby P.
        • Raichlen J.S.
        • Uno K.
        • Kataoka Y.
        • Nicholls S.J.
        Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
        Eur Heart J. 2013; 34: 3182-3190
        • Balk E.M.
        • Karas R.H.
        • Jordan H.S.
        • Kupelnick B.
        • Chew P.
        • Lau J.
        Effects of statins on vascular structure and function: a systematic review.
        Am J Med. 2004; 117: 775-790
        • Hiro T.
        • Kimura T.
        • Morimoto T.
        • Miyauchi K.
        • Nakagawa Y.
        • Yamagishi M.
        • Ozaki Y.
        • Kimura K.
        • Saito S.
        • Yamaguchi T.
        • Daida H.
        • Matsuzaki M.
        • JAPAN-ACS Investigators
        Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study).
        J Am Coll Cardiol. 2009; 54: 293-302
        • Raber L.
        • Taniwaki M.
        • Zaugg S.
        • Kelbaek H.
        • Roffi M.
        • Holmvang L.
        • Noble S.
        • Pedrazzini G.
        • Moschovitis A.
        • Luscher T.F.
        • Matter C.M.
        • Serruys P.W.
        • Juni P.
        • Garcia-Garcia H.M.
        • Windecker S.
        • IBIS 4 (Integrated Biomarkers and Imaging Study-4) Trial Investigators
        Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study.
        Eur Heart J. 2015; 36: 490-500
        • Tian J.
        • Gu X.
        • Sun Y.
        • Ban X.
        • Xiao Y.
        • Hu S.
        • Yu B.
        Effect of statin therapy on the progression of coronary atherosclerosis.
        BMC Cardiovasc Disord. 2012; 12: 70
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        • PRISMA Group
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        BMJ. 2009; 339: b2535
        • Higgins J.P.T.
        • Green S.
        Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011].
        The Cochrane Collaboration, 2011 (England: Chichester, Available at: http://www.cochrane-handbook.org. Accessed on May 17, 2015)
        • Delewi R.
        • Hirsch A.
        • Tijssen J.G.
        • Schachinger V.
        • Wojakowski W.
        • Roncalli J.
        • Aakhus S.
        • Erbs S.
        • Assmus B.
        • Tendera M.
        • Goekmen Turan R.
        • Corti R.
        • Henry T.
        • Lemarchand P.
        • Lunde K.
        • Cao F.
        • Huikuri H.V.
        • Surder D.
        • Simari R.D.
        • Janssens S.
        • Wollert K.C.
        • Plewka M.
        • Grajek S.
        • Traverse J.H.
        • Zijlstra F.
        • Piek J.J.
        Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis.
        Eur Heart J. 2014; 35: 989-998
        • Hong Y.J.
        • Jeong M.H.
        • Chung J.W.
        • Sim D.S.
        • Zhang S.
        • Gu D.
        The effects of rosuvastatin on plaque regression in patients who have a mild to moderate degree of coronary stenosis with vulnerable plaque.
        Korean Circ J. 2008; 38: 366-373
        • Hong Y.J.
        • Jeong M.H.
        • Hachinohe D.
        • Ahmed K.
        • Choi Y.H.
        • Cho S.H.
        • Hwang S.H.
        • Ko J.S.
        • Lee M.G.
        • Park K.H.
        • Sim D.S.
        • Yoon N.S.
        • Yoon H.J.
        • Kim K.H.
        • Park H.W.
        • Kim J.H.
        • Ahn Y.
        • Cho J.G.
        • Park J.C.
        • Kang J.C.
        Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
        Circ J. 2011; 75: 398-406
        • Nicholls S.J.
        • Ballantyne C.M.
        • Barter P.J.
        • Chapman M.J.
        • Erbel R.M.
        • Libby P.
        • Raichlen J.S.
        • Uno K.
        • Borgman M.
        • Wolski K.
        • Nissen S.E.
        Effect of two intensive statin regimens on progression of coronary disease.
        N Engl J Med. 2011; 365: 2078-2087
        • Guo Y.F.
        • Guo S.X.
        • Yang Y.
        • Yang Z.Y.
        • Wang Q.
        Influence of different statins in standard dose on stable plaques.
        South China J Cardiovasc Dis. 2012; 18: 576-580
        • Lee C.W.
        • Kang S.J.
        • Ahn J.M.
        • Song H.G.
        • Lee J.Y.
        • Kim W.J.
        • Park D.W.
        • Lee S.W.
        • Kim Y.H.
        • Park S.W.
        • Park S.J.
        Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
        Am J Cardiol. 2012; 109: 1700-1704
        • Stone N.J.
        • Robinson J.G.
        • Lichtenstein A.H.
        • Bairey Merz C.N.
        • Blum C.B.
        • Eckel R.H.
        • Goldberg A.C.
        • Gordon D.
        • Levy D.
        • Lloyd-Jones D.M.
        • McBride P.
        • Schwartz J.S.
        • Shero S.T.
        • Smith Jr., S.C.
        • Watson K.
        • Wilson P.W.
        • American College of Cardiology/American Heart Association Task Force on Practice Guidelines
        2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2889-2934
        • Reiner Z.
        • Catapano A.L.
        • Catapano A.L.
        • De Backer G.
        • Graham I.
        • Taskinen M.R.
        • Wiklund O.
        • Agewall S.
        • Alegria E.
        • Chapman M.J.
        • Durrington P.
        • Erdine S.
        • Halcox J.
        • Hobbs R.
        • Kjekshus J.
        • Filardi P.P.
        • Riccardi G.
        • Storey R.F.
        • Wood D.
        • European Association for Cardiovascular Prevention and Rehabilitation
        • ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees
        ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
        Eur Heart J. 2011; 32: 1769-1818
        • Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults
        Chinese guidelines on prevention and treatment of dyslipidemia in adults.
        Zhonghua Xin Xue Guan Bing Za Zhi. 2007; 35: 390-419
        • Weber C.
        • Noels H.
        Atherosclerosis: current pathogenesis and therapeutic options.
        Nat Med. 2011; 17: 1410-1422
        • Mihos C.G.
        • Salas M.J.
        • Santana O.
        The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review.
        Cardiol Rev. 2010; 18: 298-304
        • Puri R.
        • Nissen S.E.
        • Shao M.
        • Uno K.
        • Kataoka Y.
        • Kapadia S.R.
        • Tuzcu E.M.
        • Nicholls S.J.
        Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy.
        Am J Cardiol. 2014; 114: 1465-1472
        • Puri R.
        • Libby P.
        • Nissen S.E.
        • Wolski K.
        • Ballantyne C.M.
        • Barter P.J.
        • Chapman M.J.
        • Erbel R.
        • Raichlen J.S.
        • Uno K.
        • Kataoka Y.
        • Tuzcu E.M.
        • Nicholls S.J.
        Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
        Eur Heart J Cardiovasc Imaging. 2014; 15: 380-388
        • Puri R.
        • Nissen S.E.
        • Libby P.
        • Shao M.
        • Ballantyne C.M.
        • Barter P.J.
        • Chapman M.J.
        • Erbel R.
        • Raichlen J.S.
        • Uno K.
        • Kataoka Y.
        • Nicholls S.J.
        C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
        Circulation. 2013; 128: 2395-2403
        • Wlodarczyk J.
        • Sullivan D.
        • Smith M.
        Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
        Am J Cardiol. 2008; 102: 1654-1662
        • Leiter L.A.
        • Rosenson R.S.
        • Stein E.
        • Reckless J.P.
        • Schulte K.L.
        • Schleman M.
        • Miller P.
        • Palmer M.
        • Sosef F.
        • POLARIS Study Investigators
        Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.
        Atherosclerosis. 2007; 194: e154-e164
        • Lee C.W.
        • Park C.S.
        • Hwang I.
        • Kim Y.
        • Park D.W.
        • Kang S.J.
        • Lee S.H.
        • Kim Y.H.
        • Park S.W.
        • Park S.J.
        Expression of HMG-CoA reductase in human coronary atherosclerotic plaques and relationship to plaque destabilisation.
        Heart. 2011; 97: 715-720